Arbovirus Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034?
The 7 major arbovirus infection markets are expected to exhibit a CAGR of 5.56% during 2024-2034.
The arbovirus infection market has been comprehensively analyzed in IMARC's new report titled "Arbovirus Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Arbovirus infection, short for arthropod-borne viruses, refers to a class of viral diseases transmitted to humans and other vertebrates by certain types of arthropods, mainly mosquitoes, ticks, and sandflies. This viral infection can lead to a range of symptoms and health complications. Indications of the illness can vary widely depending on the specific virus involved. Common symptoms include fever, headache, joint and muscle pain, rash, and fatigue. In more severe cases, some arboviruses, such as the Zika virus, dengue virus, or West Nile virus, can lead to neurological disorders, hemorrhagic fevers, or even death. Diagnosing this infection typically involves a combination of clinical evaluation, serological tests, and molecular assays. Healthcare providers may look for specific antibodies in a patient's blood to confirm exposure to the virus. In some cases, molecular techniques like polymerase chain reaction (PCR) can be used to detect the virus's genetic material.
The increasing cases of virus diseases that are mainly transmitted to humans and animals through the bites of infected arthropods are primarily driving the arbovirus infection market. In addition to this, the inflating utilization of efficacious antiviral medications, such as ribavirin, interferon-alpha, and various other supportive therapies, to mitigate the symptoms and forestall further complications is also creating a positive outlook for the market. Moreover, the widespread adoption of preventative measures and vector control strategies, as they play a crucial role in diminishing the transmission rates of these viruses, is further bolstering the market growth. Apart from this, the rising awareness about the importance of early diagnosis and timely medical intervention, facilitated by advancements in diagnostic techniques and the availability of rapid testing kits, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of physical therapies and rehabilitation services aimed at aiding patients in regaining lost motor functions and improving their overall quality of life is also augmenting the market growth. Furthermore, the escalating application of genomic and molecular biology techniques to understand the viral mechanisms and develop targeted therapies is expected to drive the arbovirus infection market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the arbovirus infection market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for arbovirus infection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the arbovirus infection market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the arbovirus infection market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the arbovirus infection market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current arbovirus infection marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report:
Market Insights
How has the arbovirus infection market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the arbovirus infection market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the arbovirus infection market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of arbovirus infection across the seven major markets?
What is the number of prevalent cases (2018-2034) of arbovirus infection by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of arbovirus infection by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of arbovirus infection by type across the seven major markets?
How many patients are diagnosed (2018-2034) with arbovirus infection across the seven major markets?
What is the size of the arbovirus infection patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of arbovirus infection?
What will be the growth rate of patients across the seven major markets?
Arbovirus Infection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for arbovirus infection drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the arbovirus infection market?
What are the key regulatory events related to the arbovirus infection market?
What is the structure of clinical trial landscape by status related to the arbovirus infection market?
What is the structure of clinical trial landscape by phase related to the arbovirus infection market?
What is the structure of clinical trial landscape by route of administration related to the arbovirus infection market?
The arbovirus infection market has been comprehensively analyzed in IMARC's new report titled "Arbovirus Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Arbovirus infection, short for arthropod-borne viruses, refers to a class of viral diseases transmitted to humans and other vertebrates by certain types of arthropods, mainly mosquitoes, ticks, and sandflies. This viral infection can lead to a range of symptoms and health complications. Indications of the illness can vary widely depending on the specific virus involved. Common symptoms include fever, headache, joint and muscle pain, rash, and fatigue. In more severe cases, some arboviruses, such as the Zika virus, dengue virus, or West Nile virus, can lead to neurological disorders, hemorrhagic fevers, or even death. Diagnosing this infection typically involves a combination of clinical evaluation, serological tests, and molecular assays. Healthcare providers may look for specific antibodies in a patient's blood to confirm exposure to the virus. In some cases, molecular techniques like polymerase chain reaction (PCR) can be used to detect the virus's genetic material.
The increasing cases of virus diseases that are mainly transmitted to humans and animals through the bites of infected arthropods are primarily driving the arbovirus infection market. In addition to this, the inflating utilization of efficacious antiviral medications, such as ribavirin, interferon-alpha, and various other supportive therapies, to mitigate the symptoms and forestall further complications is also creating a positive outlook for the market. Moreover, the widespread adoption of preventative measures and vector control strategies, as they play a crucial role in diminishing the transmission rates of these viruses, is further bolstering the market growth. Apart from this, the rising awareness about the importance of early diagnosis and timely medical intervention, facilitated by advancements in diagnostic techniques and the availability of rapid testing kits, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of physical therapies and rehabilitation services aimed at aiding patients in regaining lost motor functions and improving their overall quality of life is also augmenting the market growth. Furthermore, the escalating application of genomic and molecular biology techniques to understand the viral mechanisms and develop targeted therapies is expected to drive the arbovirus infection market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the arbovirus infection market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for arbovirus infection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the arbovirus infection market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the arbovirus infection market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the arbovirus infection market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current arbovirus infection marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report:
Market Insights
How has the arbovirus infection market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the arbovirus infection market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the arbovirus infection market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of arbovirus infection across the seven major markets?
What is the number of prevalent cases (2018-2034) of arbovirus infection by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of arbovirus infection by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of arbovirus infection by type across the seven major markets?
How many patients are diagnosed (2018-2034) with arbovirus infection across the seven major markets?
What is the size of the arbovirus infection patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of arbovirus infection?
What will be the growth rate of patients across the seven major markets?
Arbovirus Infection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for arbovirus infection drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the arbovirus infection market?
What are the key regulatory events related to the arbovirus infection market?
What is the structure of clinical trial landscape by status related to the arbovirus infection market?
What is the structure of clinical trial landscape by phase related to the arbovirus infection market?
What is the structure of clinical trial landscape by route of administration related to the arbovirus infection market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ARBOVIRUS INFECTION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.4 Market Overview (2018-2023) and Forecast (2024-2034?)
4.5 Competitive Intelligence
5 ARBOVIRUS INFECTION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ARBOVIRUS INFECTION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 ARBOVIRUS INFECTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ARBOVIRUS INFECTION - UNMET NEEDS
10 ARBOVIRUS INFECTION - KEY ENDPOINTS OF TREATMENT
11 ARBOVIRUS INFECTION - MARKETED PRODUCTS
11.1 List of Arbovirus Infection Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Clinical Trial Results
11.1.1.4 Safety and Efficacy
11.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
12 ARBOVIRUS INFECTION - PIPELINE DRUGS
12.1 List of Arbovirus Infection Pipeline Drugs Across the Top 7 Markets
12.1.1 PIZV - Takeda
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 VLA 1601 - Valneva
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 VLA 1553 - Valneva
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 CHIKV VLP - Bavarian Nordic
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 mRNA1893 - Moderna Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. ARBOVIRUS INFECTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ARBOVIRUS INFECTION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ARBOVIRUS INFECTION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Arbovirus Infection - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034?)
15.2.2 Arbovirus Infection - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034?)
15.3 Market Scenario - United States
15.3.1 Arbovirus Infection - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034?)
15.3.2 Arbovirus Infection - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034?)
15.3.3 Arbovirus Infection - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Arbovirus Infection - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034?)
15.4.2 Arbovirus Infection - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034?)
15.4.3 Arbovirus Infection - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Arbovirus Infection - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034?)
15.5.2 Arbovirus Infection - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034?)
15.5.3 Arbovirus Infection - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Arbovirus Infection - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034?)
15.6.2 Arbovirus Infection - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034?)
15.6.3 Arbovirus Infection - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Arbovirus Infection - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034?)
15.7.2 Arbovirus Infection - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034?)
15.7.3 Arbovirus Infection - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Arbovirus Infection - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034?)
15.8.2 Arbovirus Infection - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034?)
15.8.3 Arbovirus Infection - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Arbovirus Infection - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034?)
15.9.2 Arbovirus Infection - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034?)
15.9.3 Arbovirus Infection - Access and Reimbursement Overview
16 ARBOVIRUS INFECTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ARBOVIRUS INFECTION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ARBOVIRUS INFECTION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ARBOVIRUS INFECTION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.4 Market Overview (2018-2023) and Forecast (2024-2034?)
4.5 Competitive Intelligence
5 ARBOVIRUS INFECTION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ARBOVIRUS INFECTION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 ARBOVIRUS INFECTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ARBOVIRUS INFECTION - UNMET NEEDS
10 ARBOVIRUS INFECTION - KEY ENDPOINTS OF TREATMENT
11 ARBOVIRUS INFECTION - MARKETED PRODUCTS
11.1 List of Arbovirus Infection Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Clinical Trial Results
11.1.1.4 Safety and Efficacy
11.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
12 ARBOVIRUS INFECTION - PIPELINE DRUGS
12.1 List of Arbovirus Infection Pipeline Drugs Across the Top 7 Markets
12.1.1 PIZV - Takeda
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 VLA 1601 - Valneva
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 VLA 1553 - Valneva
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 CHIKV VLP - Bavarian Nordic
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 mRNA1893 - Moderna Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. ARBOVIRUS INFECTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ARBOVIRUS INFECTION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ARBOVIRUS INFECTION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Arbovirus Infection - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034?)
15.2.2 Arbovirus Infection - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034?)
15.3 Market Scenario - United States
15.3.1 Arbovirus Infection - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034?)
15.3.2 Arbovirus Infection - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034?)
15.3.3 Arbovirus Infection - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Arbovirus Infection - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034?)
15.4.2 Arbovirus Infection - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034?)
15.4.3 Arbovirus Infection - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Arbovirus Infection - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034?)
15.5.2 Arbovirus Infection - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034?)
15.5.3 Arbovirus Infection - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Arbovirus Infection - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034?)
15.6.2 Arbovirus Infection - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034?)
15.6.3 Arbovirus Infection - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Arbovirus Infection - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034?)
15.7.2 Arbovirus Infection - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034?)
15.7.3 Arbovirus Infection - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Arbovirus Infection - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034?)
15.8.2 Arbovirus Infection - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034?)
15.8.3 Arbovirus Infection - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Arbovirus Infection - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034?)
15.9.2 Arbovirus Infection - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034?)
15.9.3 Arbovirus Infection - Access and Reimbursement Overview
16 ARBOVIRUS INFECTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ARBOVIRUS INFECTION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ARBOVIRUS INFECTION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
